Attached files
| file | filename |
|---|---|
| EX-32.1 - EXHIBIT 32.1 - SUNOVION CNS DEVELOPMENT CANADA ULC | v433521_ex32-1.htm |
| EX-31.1 - EXHIBIT 31.1 - SUNOVION CNS DEVELOPMENT CANADA ULC | v433521_ex31-1.htm |
| EX-21.1 - EXHIBIT 21.1 - SUNOVION CNS DEVELOPMENT CANADA ULC | v433521_ex21-1.htm |
| EX-31.2 - EXHIBIT 31.2 - SUNOVION CNS DEVELOPMENT CANADA ULC | v433521_ex31-2.htm |
| EX-16.1 - EXHIBIT 16.1 - SUNOVION CNS DEVELOPMENT CANADA ULC | v433521_ex16-1.htm |
| EX-23.1 - EXHIBIT 23.1 - SUNOVION CNS DEVELOPMENT CANADA ULC | v433521_ex23-1.htm |
| 10-K - FORM 10-K - SUNOVION CNS DEVELOPMENT CANADA ULC | v433521_10k.htm |
Exhibit 23.2
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the Registration Statement on Form S-8 (File No. 333-205929) of Cynapsus Therapeutics Inc. (the “Company”), of our report dated April 8, 2014, relating to the Company’s consolidated statement of financial position as at December 31, 2013, and the Company’s consolidated statements of loss and comprehensive loss, changes in shareholders’ equity and cash flows for the year ended December 31, 2013, which appear in this Annual Report on Form 10-K.
McGovern, Hurley, Cunningham, LLP
/s/ McGovern, Hurley, Cunningham, LLP
Chartered Accountants
Licensed Public Accountants
Toronto, Canada
March 9, 2016